SCHEDULE: Intracoastal Capital Reports 4.99% Stake in Salarius Pharma

Intracoastal Capital LLC and its managers, Mitchell P. Kopin and Daniel B. Asher, reported a passive beneficial ownership of 4.99% in Salarius Pharmaceuticals, Inc. common stock.

Summary

• Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in Salarius Pharmaceuticals, Inc.
• The class of securities is Common Stock, par value $0.0001 per share, with CUSIP Number 79400X503.
• As of November 14, 2025, the Reporting Persons beneficially own an aggregate of 187,295 shares of Common Stock.
• This beneficial ownership represents approximately 4.99% of the outstanding Common Stock, calculated based on 3,566,117 shares outstanding after a public offering, plus the 187,295 shares issuable upon warrant exercise.
• The shares are primarily issuable upon the exercise of Intracoastal Warrant 1.
• The warrants held by Intracoastal Capital LLC include blocker provisions that prevent the holder from exercising them to the extent that such exercise would result in beneficial ownership exceeding 4.99% of the Common Stock.
• Without these blocker provisions, the Reporting Persons would have been deemed to beneficially own 667,016 shares of Common Stock as of November 14, 2025.
• The filing indicates a passive investment purpose, stating that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The filing is neutral to slightly positive, indicating a significant passive investment by an institutional entity. The blocker provisions are a technicality for regulatory compliance rather than a negative operational factor. The investment itself can be seen as a vote of confidence.

Positives

• A significant institutional investor, Intracoastal Capital LLC, has disclosed a passive stake in Salarius Pharmaceuticals, which may signal confidence in the company's long-term prospects.
• The investment is explicitly passive, indicating no immediate intent to disrupt company operations or strategic direction.

Negatives

• The presence of blocker provisions in the warrants limits the reported beneficial ownership to just under 5%, which might technically obscure the full potential stake if not for regulatory thresholds.

Risks

• The existence of warrants, even with blocker provisions, represents a potential for future dilution if these warrants are fully exercised, although currently limited by the 4.99% threshold.

Future Outlook

NA

Industry Context

This filing indicates a notable passive investment by Intracoastal Capital in Salarius Pharmaceuticals, a biotechnology company. Such investments are common in the biotech sector, where institutional investors often take positions in companies with promising drug pipelines or technologies, without necessarily seeking active control.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by an institutional investor may be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a substantial passive investor may influence strategic decisions, though the investor explicitly states no intent to influence control.

Key Dates

Recommendation

The filing indicates a passive investment by Intracoastal Capital, which is a neutral to slightly positive signal. It does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. The 4.99% stake is significant but explicitly non-controlling, suggesting no immediate catalyst for major price movement based solely on this ownership change. Investors should 'hold' and await further operational or financial updates from Salarius Pharmaceuticals.

Keywords

Salarius Pharmaceuticals, Intracoastal Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, SRNE